230 F. Supp. 3d 3
D. Mass.2017Background
- Plaintiffs Li Liu and Dr. Emily Liu, administrators of the estate of Dr. Zhensheng Liu, sued Boehringer Ingelheim entities for negligent failure to warn, negligent design defect, and negligent design and testing after Dr. Liu died from cranial bleeding while on Pradaxa.
- Pradaxa (dabigatran) is an FDA‑approved anticoagulant prescribed for non‑valvular atrial fibrillation; Dr. Liu (age 80+) was prescribed Pradaxa in 2011 and died after a 2012 fall with subsequent intracranial hemorrhage.
- Plaintiffs claim defendants knew or should have known of increased bleeding risk in patients over 80 and failed to adequately warn physicians or patients; they rely on expert affidavits (Dr. Molofsky and Dr. Emily Liu).
- Defendants moved for summary judgment arguing (1) plaintiffs’ design claims lack evidence and are preempted, (2) no proximate cause because the prescribing physician would not have changed his decision, and (3) Pradaxa’s label provided adequate warnings under Massachusetts law.
- The court granted summary judgment on negligent design and negligent design/testing (insufficient evidence). It denied summary judgment on failure‑to‑warn (label adequacy) and proximate cause limited to whether the label should have warned specifically about risks for patients over age 80.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Defective design / negligent design & testing | Pradaxa had safer alternative designs and was negligently designed/tested | No evidence supporting design‑defect or negligent testing claims | Granted for defendants — plaintiffs produced no evidence |
| Adequacy of Pradaxa label (failure to warn) | Label did not adequately warn of increased bleeding risk for patients >80; experts say warning should have specified age risk | Label was plain, comprehensive; learned intermediary doctrine applies; label adequate as matter of law or no causation | Not resolved on summary judgment — triable issue remains whether label adequately warned about risks to >80 patients |
| Learned intermediary doctrine applicability | Plaintiffs say Dr. Liu (a physician) could act as his own decisionmaker, negating the doctrine | Defendants say prescribing physician is the learned intermediary; Dr. Emily Liu admitted she relied on prescribing physicians and lacked Pradaxa experience | Court applied learned intermediary doctrine — plaintiffs failed to show it did not apply |
| Proximate causation (would physician have heeded adequate warning?) | If adequately warned, prescribing physician would have chosen differently for an >80 patient; presumption that physician would heed adequate warning | Physician testimony indicated he would have still prescribed Pradaxa despite known bleeding risks, rebutting the presumption | Mixed: defendants rebutted presumption as to internal hemorrhage causation, but a triable issue remains on narrow theory that a warning about age‑specific risk would have changed prescribing decision |
Key Cases Cited
- Anderson v. Liberty Lobby, 477 U.S. 242 (summary judgment standard)
- Celotex Corp. v. Catrett, 477 U.S. 317 (summary judgment burden on movant/nonmovant)
- Reeves v. Sanderson Plumbing Prods., 530 U.S. 133 (drawing inferences for nonmovant at summary judgment)
- MacDonald v. Ortho Pharm. Corp., 394 Mass. 131 (adequacy of warning; jury question)
- Cottam v. CVS Pharmacy, 436 Mass. 316 (learned intermediary; inference physician would follow adequate warning)
- Garside v. Osco Drug, Inc., 976 F.2d 77 (failure‑to‑warn burden‑shifting framework under Massachusetts law)
- Wyeth v. Levine, 555 U.S. 555 (state failure‑to‑warn claims and manufacturer duty to ensure adequate warnings)